You are here
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Diplomat Pharmacy, Inc. To Contact The Firm
NEW YORK, March 15, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Diplomat Pharmacy, Inc. ("Diplomat" or the "Company")(NYSE:DPLO) of the April 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Diplomat stock or options between February 26, 2018 and February 21, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/DPLO. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased Diplomat securities between February 26, 2018 and February 21, 2019 (the "Class Period"). The case, Riehm v. Diplomat Pharmacy, Inc. et al., No. 19-cv-01369 was filed on February 24, 2019.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior.
On February 22, 2019, Diplomat filed a Form 8-K with the Securities and Exchange Commission, announcing it was postponing the release of its Form 10-K for the fiscal year ended December 31, 2018 due to a "recent determination" that it would need to record a non-cash impairment charge upwards of approximately $630 million relating to 2017 acquisitions for its PBM business.
On this news, Diplomat's share price fell from 13.46 per share on February 21, 2019 to a closing price of 5.87 on February 22, 2019: a $7.59 or a 56.39% drop.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Diplomat's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lead-plaintiff-deadline-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-50-000-investing-in-diplomat-pharmacy-inc-to-contact-the-firm-300813352.html
SOURCE Faruqi & Faruqi, LLP